Date: 2012-05-24
Type of information: R&D agreement
Compound: LAS186323
Company: Almirall (Spain) ASLAN Pharmaceuticals (Singapore)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: R&D
licensing
commercialisation
Action mechanism: LAS186323 is a second generation DHODH ( dihydroorotate dehydrogenase) inhibitor that exhibited no signs of hepatotoxicity or hypertension in laboratory testing, as well as linear pharmacokinetics in a Phase I single ascending dose study in healthy volunteers.
Disease: rheumatoid arthritis
Details: Almirall and ASLAN Pharmaceuticals have signed a global agreement on a novel treatment for rheumatoid arthritis, LAS186323. The product comes from Almirall’s research and is currently in Phase I development for rheumatoid arthritis. Under the agreement, ASLAN will fund and develop LAS186323 to the end of Phase II through a development program conducted in the Asia-Pacific region. Upon achievement of proof of concept, a global partner for Phase III development and commercialization will be identified.
Financial terms: Financial terms were not disclosed.
Latest news:
